This clinical trial is focused on studying a condition called Geographic Atrophy, which is a type of vision loss that occurs as a result of Age-related Macular Degeneration (AMD). The study will use a treatment known as JNJ-81201887, which is a solution for injection. This treatment involves a special type of virus called an Adeno-associated virus that has been modified to carry a specific protein, soluble CD59, which may help in managing the condition. The purpose of the study is to assess the long-term safety and how well patients tolerate this treatment after it has been injected into the eye.

Participants in this study will have previously been involved in earlier studies where they received either the JNJ-81201887 treatment or a sham treatment, which is a procedure that mimics the treatment but does not contain the active substance. The study will monitor participants over time to observe any side effects or changes in their condition. This will include regular eye examinations and imaging tests to check the health of the retina, which is the part of the eye affected by Geographic Atrophy.

In addition to JNJ-81201887, the study will also involve the use of Prednisone, a medication that is commonly used to reduce inflammation. Participants may receive Prednisone in tablet form or a placebo that looks like the Prednisone tablets but does not contain the active ingredient. The study aims to gather comprehensive data on the safety of these treatments and their effects on the participants’ vision and overall health.